Maria João Lúcio, Maria Luiza Pereira, Catarina Barata, Carlos Lopes, Jafar Aljazeeri
{"title":"Bronchial Thermoplasty in Severe Asthma: Bridging Randomised and Real-World Evidence: A Systematic Review and Meta-Analysis.","authors":"Maria João Lúcio, Maria Luiza Pereira, Catarina Barata, Carlos Lopes, Jafar Aljazeeri","doi":"10.3390/arm94050077","DOIUrl":"10.3390/arm94050077","url":null,"abstract":"<p><p><b>Introduction</b>: Bronchial thermoplasty (BT) reduces airway smooth muscle and may benefit severe asthma, but its role alongside biologics remains unclear. We assessed randomised and real-world evidence on efficacy and safety. <b>Methods</b>: We searched PubMed, Scopus, and Cochrane Library for RCTs and observational studies of BT in adults with severe uncontrolled asthma, analysing them separately. <b>Results</b>: Twenty studies were included (five RCTs, 15 observational). In RCTs, BT improved asthma-related quality of life (AQLQ;MD, 0.69; 95% CI 0.30-1.09), asthma control (ACQ; MD,-0.64; 95%CI, -1.10 to -0.19), and morning peak expiratory flow (MD, 20.62 L/min; 95% CI, 4.92-36.32), but did not improve rescue medication use or symptom-free-days. BT increased the risk of hospitalisation during the treatment period (RR, 3.50; 95%CI, 1.26-9.68), with no significant excess thereafter. Real-world studies showed improvements in AQLQ (MD,1.38; 95%CI, 0.97-1.80), ACQ (MD,-1.24; 95%CI, -1.86 to -0.62), and annualised exacerbation rates (MD, -3.79 exacerbations/patient-year; 95%CI, -6.98 to -0.61). Evidence suggested a possible, inconsistent corticosteroid-sparing effect; data on biologics and long-term safety were limited. <b>Conclusions</b>: BT improved asthma-related quality of life and control, mainly in trials without sham controls, but increased short-term hospitalisation risk. Real-world findings were similar but came from uncontrolled studies. BT is not an established alternative to biologics, but may suit carefully selected patients with severe asthma who cannot use or do not respond to them.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701635/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stroke Lesion Location Is Associated with Dynamic Inspiratory Performance: A Cross-Sectional Study.","authors":"Ho-Chieh Kuo, Guanghua Liu, Zongye Zhong, Bangzhong Liu, Xiaokai Zhang, Mingfang Shi","doi":"10.3390/arm94050076","DOIUrl":"10.3390/arm94050076","url":null,"abstract":"<p><strong>Background/objectives: </strong>We examined whether respiratory performance differed among broad stroke lesion-location categories.</p><p><strong>Methods: </strong>This exploratory single-center cross-sectional analysis combined pre-intervention assessments from 20 participants in an earlier trial with 60 subsequently recruited participants. The 80 patients were classified into frontal lobe (<i>n</i> = 27), basal ganglia region (<i>n</i> = 26), or brainstem (<i>n</i> = 27) categories. Peak inspiratory flow (PIF), strength index (S-Index), and five conventional respiratory outcomes were assessed. Holm correction was applied across seven outcomes. Linear models used type 3 heteroscedasticity-consistent (HC3) robust standard errors and the original six clinical covariates. Additional PIF analyses incorporated time since stroke, National Institutes of Health Stroke Scale (NIHSS), or modified Barthel Index (MBI), and restricted the sample to ischemic or first-ever stroke.</p><p><strong>Results: </strong>Only PIF retained an unadjusted group association after Holm correction (adjusted <i>p</i> = 0.008). The adjusted overall lesion-location association also survived correction (adjusted <i>p</i> = 0.009). PIF was 0.625 L/s higher in the basal ganglia region than in the brainstem group (95% confidence interval [CI], 0.282-0.967). This contrast persisted with additional clinical adjustment in the full cohort and in ischemic stroke. Evidence weakened in first-ever stroke; with MBI adjustment, the contrast was 0.381 L/s (95% CI, -0.067-0.829).</p><p><strong>Conclusions: </strong>Broad lesion-location categories were associated with PIF in this selected cohort. The findings remain exploratory and cannot fully separate anatomical associations from stroke severity, disability, unmeasured clinical factors, or measurement limitations.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katarzyna Sienkiewicz, Jadwiga Fijałkowska, Małgorzata Jelitto, Jakub Byczkowski, Michał Koliński, Edyta Szurowska, Witold Rzyman
{"title":"Opportunistic Cardiovascular Assessment During Lung Cancer Screening with Low-Dose Computed Tomography: A New Window for Prevention.","authors":"Katarzyna Sienkiewicz, Jadwiga Fijałkowska, Małgorzata Jelitto, Jakub Byczkowski, Michał Koliński, Edyta Szurowska, Witold Rzyman","doi":"10.3390/arm94050075","DOIUrl":"10.3390/arm94050075","url":null,"abstract":"<p><p>Population-based lung cancer screening with low-dose computed tomography (LDCT) is expanding across Europe, including a publicly funded Polish programme starting in October 2026. Because screening-eligible individuals share substantial tobacco-related cardiovascular risk, LDCT also offers cardiovascular risk assessment without additional radiation. We conducted a narrative review of the PubMed literature published up to September 2026, prioritising guidelines, lung cancer screening cohorts and systematic reviews. We summarise the cardiovascular findings on non-contrast, non-electrocardiography (ECG)-gated LDCT: coronary artery, aortic valve, mitral annular and thoracic aortic calcification, ascending aortic dilatation, pericardial effusion, and pulmonary artery enlargement, as well as investigational cardiac volumetry, epicardial adipose tissue and artificial intelligence (AI)-assisted quantification. We grade each finding by reportability, defined downstream action and supporting evidence, and align reporting thresholds with the European Respiratory Society/European Society of Thoracic Imaging (ERS/ESTI) statement on incidental findings. LDCT cannot replace dedicated cardiac imaging or establish haemodynamic diagnoses. The prognostic value of coronary and aortic valve calcification and of ascending aortic dilatation is established, whereas the evidence for mitral annular calcification and pulmonary artery enlargement is more limited; observational data indicate that reporting these markers changes preventive management, but whether this improves cardiovascular outcomes has not yet been demonstrated. Standardised reporting, proportionate thresholds, and coordinated pathways linking radiology, pulmonology, primary care and cardiology are needed to translate incidental cardiovascular findings into scalable prevention and should be evaluated in implementation studies.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patrizia Russo, Stefania Proietti, Laura Vitiello, Simona Pace, Carlo Tomino, Giorgio Felzani, Giulia Prinzi, Stefano Bonassi
{"title":"Behavioral Adaptation and Response to Pulmonary Rehabilitation in Older Patients with Advanced COPD: Beyond Clinical and Immune Biomarkers.","authors":"Patrizia Russo, Stefania Proietti, Laura Vitiello, Simona Pace, Carlo Tomino, Giorgio Felzani, Giulia Prinzi, Stefano Bonassi","doi":"10.3390/arm94050074","DOIUrl":"10.3390/arm94050074","url":null,"abstract":"<p><p>Patients with advanced chronic obstructive pulmonary disease (COPD) respond differently to pulmonary rehabilitation (PR), and respiratory impairment alone might not fully explain this variability. Behavioral adaptation may contribute to differences in rehabilitation response. We studied 102 patients with advanced COPD (GOLD III-IV) who completed a 3-week multidisciplinary PR program. Functional response was assessed by change in six-minute walking distance (6MWD). Clinical, functional, psychological, lifestyle, and immune characteristics were evaluated, including coping strategies measured with the Brief COPE, Torque Teno virus (TTV) viremia, and circulating T-cell subsets. Exploratory mediation analyses examined whether coping strategies contributed to the association between age and rehabilitation response. Greater improvement in 6MWD was associated with higher active coping and planning scores, while self-distraction also differed across response groups. Planning scores were higher in good responders than in non-responders (7.10 ± 1.35 vs. 5.05 ± 1.93, respectively; <i>p</i> < 0.001). Planning was the only coping strategy showing a statistically significant indirect effect in the exploratory mediation analysis. The estimated proportion mediated was approximately 26.5%, although the wide confidence interval indicated substantial uncertainty. These findings should be interpreted cautiously given the observational design and the assessment of multiple coping strategies. Conventional physiological measures, lifestyle characteristics, and immune biomarkers-including TTV viremia and circulating T-cell subsets-did not significantly distinguish rehabilitation response groups. Planning and active coping were associated with response in both sexes. A separate pilot randomized study, IMPROVE (<i>n</i> = 36), was subsequently conducted to investigate whether structured psychological support could influence coping strategies and help maintain the benefits of PR. At six months, patients receiving psychological support showed better maintenance of rehabilitation benefits, alongside improvements in psychological well-being, quality of life, and selected coping strategies. These findings provide preliminary evidence that coping-related characteristics may be modifiable; however, IMPROVE was a separate exploratory intervention study and was not designed to validate the observational findings. Assessment of coping strategies may complement clinical and functional evaluation and help identify patients who could benefit from tailored psychological support. Their clinical utility and the effectiveness of targeted interventions require confirmation in larger prospective studies.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701965/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jyoti Bajpai, Akshyaya Pradhan, Gaurav Manek, Shivani Maurya, Surya Kant, Marco Alfonso Perrone
{"title":"Efficacy and Safety of Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.","authors":"Jyoti Bajpai, Akshyaya Pradhan, Gaurav Manek, Shivani Maurya, Surya Kant, Marco Alfonso Perrone","doi":"10.3390/arm94050073","DOIUrl":"10.3390/arm94050073","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with high morbidity and mortality. Inhaled treprostinil showed pulmonary vascular and lung-function signals in pulmonary hypertension associated with Interstitial lung disease (PH-ILD) and was subsequently tested in IPF trials.</p><p><strong>Objectives: </strong>This systematic review and meta-analysis assessed the efficacy and safety of inhaled treprostinil in adults with IPF.</p><p><strong>Methods: </strong>PubMed, Google Scholar and the Cochrane Library/CENTRAL were searched for records published from January 2000 to 2026. A random-effects meta-analysis used the DerSimonian-Laird tau squared and inverse-variance weighting methods. Continuous outcomes were pooled as generic inverse-variance effects from reported estimates and 95% confidence intervals. Hazard ratios were pooled on the log scale. Safety outcomes were pooled as risk ratios from event counts.</p><p><strong>Results: </strong>The searches identified 1552 records. After deduplication, 379 records were screened and 85 full-text reports were assessed. Eleven reports were included in the systematic review. TETON-1 and TETON-2 were the two direct-IPF randomized trials within the coordinated TETON program eligible for primary meta-analysis. Inhaled treprostinil improved absolute forced vital capacity (FVC) change at 52 weeks compared with placebo (MD 111.28 mL, 95% CI 77.61 to 144.95, <i>p</i> < 0.001; I squared 8.5%). Clinical worsening was reduced (HR 0.69, 95% CI 0.57 to 0.84, <i>p</i> < 0.001; I squared 0.0%). Acute exacerbation was lower in pooled analysis (HR 0.52, 95% CI 0.30 to 0.91, <i>p</i> = 0.022), while all-cause mortality did not differ significantly (HR 0.70, 95% CI 0.47 to 1.05, <i>p</i> = 0.086). Adverse-event discontinuation, cough and headache were more frequent with treprostinil.</p><p><strong>Conclusions: </strong>In direct IPF randomized evidence, inhaled treprostinil preserved lung function and reduced clinical worsening at 52 weeks.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patrizia Russo, Laura Vitiello, Carlo Tomino, Giorgio Felzani, Massimo Fini, Stefano Bonassi
{"title":"An Integrated Biological Model for Precision Pulmonary Rehabilitation in COPD.","authors":"Patrizia Russo, Laura Vitiello, Carlo Tomino, Giorgio Felzani, Massimo Fini, Stefano Bonassi","doi":"10.3390/arm94050072","DOIUrl":"10.3390/arm94050072","url":null,"abstract":"<p><p>Pulmonary rehabilitation improves symptoms, exercise capacity and quality of life in chronic obstructive pulmonary disease (COPD), although patients with similar clinical characteristics often show different responses. This review summarizes the biological determinants of rehabilitation responsiveness identified through more than 10 years of translational research. Evidence from longitudinal studies of elderly patients with severe COPD undergoing standardized pulmonary rehabilitation was integrated with clinical, functional, molecular, immunological, cognitive, behavioural and lifestyle data, including long-term follow-up. Baseline DNA damage was markedly increased and further rose during rehabilitation (19.6 ± 7.3% vs. 21.8 ± 7.2% tail intensity) despite significant functional improvement. FKBP5 rs4713916 was the only genetic variant associated with better rehabilitation outcomes. Daily vegetable intake independently predicted treatment success, whereas smoking was associated with oxidative DNA damage, immune alterations and higher Torque Teno Virus (TTV) load. TTV ≥ 4 log10 copies/mL was associated with increased regulatory T cells, reduced α7 nicotinic acetylcholine receptor expression (31% vs. 52%; <i>p</i> = 0.023) and shorter 5-year survival (609 ± 160 vs. 937 ± 94 days; <i>p</i> = 0.017). Active Coping, Planning and Self-Distraction were the behavioural strategies most strongly associated with rehabilitation response. Cognitive impairment and obesity-related immune regulation further contributed to patient heterogeneity. These observations suggest that rehabilitation responsiveness reflects the interaction of genomic, immune, behavioural and lifestyle factors. Their integration may improve patient stratification and support the development of precision pulmonary rehabilitation.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pleural and Thoracic Air-Leak Complications After Hematopoietic Cell Transplantation: Diagnosis and Procedural Management.","authors":"Aryan Shiari, Lamia Aljundi, Ayman O Soubani","doi":"10.3390/arm94050071","DOIUrl":"10.3390/arm94050071","url":null,"abstract":"<p><p>Pleural and thoracic air-leak complications after hematopoietic cell transplantation (HCT) are clinically important but underrepresented in broad post-transplant pulmonary reviews. Direct evidence is concentrated in adult allogeneic HCT. In a cohort of 618 adults, clinically significant pleural effusion had a 1-year cumulative incidence of 9.9% (95% confidence interval, 7.7-12.5%). A separate computed tomography-based cohort of 178 first allogeneic HCT recipients reported a day-100 cumulative incidence of 41.0%; these estimates are not directly comparable because the populations, ascertainment methods, endpoints, and follow-up differed. In 50 HCT recipients undergoing thoracentesis, a specific diagnosis was established in 26%, with 5 pneumothoraces and 0 hemothoraces. Thoracic air-leak syndrome is uncommon but carries poor outcomes in reported adult and pediatric series. This focused narrative review distinguishes direct HCT evidence from data extrapolated from hematologic malignancy, general pleural practice, critical care, interventional radiology, and cellular therapy. We organize evaluation by urgency, transplant phase, and radiographic pattern; define chronic graft-versus-host disease serositis as a diagnosis of exclusion; summarize chylothorax and pleural infection management; and provide procedure-specific safety considerations for thoracentesis, small-bore drainage, indwelling pleural catheters, intrapleural enzyme therapy, and pleural biopsy. No prospective HCT-specific trials validate these procedural pathways. Clinicians should therefore use ultrasound or image guidance; apply procedure-specific rather than uniform hemostatic thresholds; and integrate infection risk, platelet trajectory, anticoagulant exposure, oxygenation, operator setting, and expected benefit. The two clinical frameworks presented are proposed and non-validated.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ivan Kopitovic, Sanja Dimic-Janjic, Mihailo Stjepanovic, Sanja Hromis, Biljana Zvezdin, Miroslav P Ilic, Violeta Kolarov, Rade Milic, Ivan Cekerevac, Vojislav Cupurdija, Ivana Buha, Jelena Jankovic, Maja Omcikus, Nikola Trboljevac, Ivana Stankovic, Marija Vukoja
{"title":"Deciphering the Benefits and Risks of Single-Inhaler Triple Therapy in COPD.","authors":"Ivan Kopitovic, Sanja Dimic-Janjic, Mihailo Stjepanovic, Sanja Hromis, Biljana Zvezdin, Miroslav P Ilic, Violeta Kolarov, Rade Milic, Ivan Cekerevac, Vojislav Cupurdija, Ivana Buha, Jelena Jankovic, Maja Omcikus, Nikola Trboljevac, Ivana Stankovic, Marija Vukoja","doi":"10.3390/arm94050070","DOIUrl":"10.3390/arm94050070","url":null,"abstract":"<p><p>Single-inhaler triple therapy (SITT) combines an inhaled corticosteroid (ICS; for example, fluticasone furoate, budesonide, or beclometasone dipropionate), a long-acting β2-agonist (LABA; for example, vilanterol or formoterol fumarate), and a long-acting muscarinic antagonist (LAMA; for example, umeclidinium or glycopyrronium bromide) in one device. Triple pharmacological therapy reduces exacerbations in selected patients with chronic obstructive pulmonary disease (COPD), but its effects on mortality and cardiovascular outcomes remain uncertain. This structured narrative review summarizes randomized trials, observational comparative-effectiveness studies, target trial emulations, systematic reviews, and health technology assessments published between 2015 and 2026. We grouped the evidence by comparator: LABA/LAMA, ICS/LABA, multiple-inhaler triple therapy (MITT), and ICS continuation versus withdrawal, because each comparison addresses a different clinical question. Pivotal trials and evidence syntheses consistently showed fewer moderate-to-severe exacerbations with triple therapy, with reported rate ratios of approximately 0.69-0.93. Mortality signals from IMPACT and ETHOS are clinically important, but previous ICS use and ICS withdrawal among participants assigned to ICS-free comparators make these findings difficult to interpret. Observational cardiovascular findings are also uncertain because residual confounding, treatment selection, exposure misclassification, outcome misclassification, and differences in baseline disease severity limit causal interpretation. Compared with MITT, the main advantages of SITT are simpler treatment and possible improvements in adherence and persistence, not greater pharmacological potency. Treatment decisions should consider exacerbation history, repeated blood eosinophil counts, pneumonia risk, cardiovascular disease, previous ICS exposure and response, inhaler technique, device suitability, and patient preference. Trials in patients with documented absence of previous ICS use and well-designed target trial emulations are needed to determine whether the observed mortality and cardiovascular associations are causal.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Banu Ayse Birlik, Oumayma Hamlaoui, Hakan Tozan, Safa Bhar Layeb, Mohammed Ait El Fqih
{"title":"Extracorporeal Membrane Oxygenation (ECMO) Prediction of Mortality and Integrated Complication with Infection Risk Assessment by Machine Learning: Structured Narrative Review.","authors":"Banu Ayse Birlik, Oumayma Hamlaoui, Hakan Tozan, Safa Bhar Layeb, Mohammed Ait El Fqih","doi":"10.3390/arm94050069","DOIUrl":"10.3390/arm94050069","url":null,"abstract":"<p><p><b>Background:</b> Extracorporeal membrane oxygenation (ECMO) is an extremely complex life-saving treatment that is performed on patients who are in severe cardiac and/or respiratory failure. Even with all the technological progress, ECMO is a procedure with high mortality and significant morbidity, making it important to predict the risks of ECMO in a timely and accurate manner. <b>Objective:</b> To offer a narrative review of the machine learning (ML) based risk prediction models currently used for ECMO, with particular focus on multi-outcome prediction-mortality, complications and infections. <b>Methods:</b> Structured narrative review of relevant literature was undertaken in PubMed, Web of Science, Scopus and IEEE Xplore from 2000 to August 2025. Eligible studies comprised machine-learning or artificial-intelligence algorithms to predict clinically important ECMO outcomes and in ECMO-supported patients. Studies that did not include conventional statistical methods, non-ECMO patient populations, or articles that presented editorials, commentaries, or articles lacking clinically relevant prediction outcomes were excluded. Titles and abstracts were screened; full text assessed for eligibility and extracted data organized using the CHARMS framework. <b>Results:</b> 25 studies were included, and these were divided into four areas, namely, mortality prediction, complication prediction (neurological, bleeding, thrombosis), requirement for ECMO and process management, and hospital readmission. In all these areas, ML models consistently showed better performance than traditional risk scores, picking up the high-dimensional interactions and nonlinear relationships. But the majority of current models are outcome-specific and use mostly static or pre-ECMO data. Of note, no potentially eligible ECMO-specific machine-learning model to predict incident secondary infection during ECMO support was found despite the impact of infection on outcomes, length of stay, antimicrobial usage, and health-care costs. <b>Conclusions:</b> The current evidence suggests that there is a shift in approach from traditional scoring methods to predictive approaches using ML. However, there are still key missing elements such as the lack of incorporation of dynamic physiological data, the lack of incorporation of immunological markers, and the lack of multi-outcome predictive approaches. These limitations need to be overcome to build clinically actionable decision-support systems. ML-based models are very promising in improving risk stratification in ECMO. Other studies should be conducted to create multi-outcome prediction models which incorporate mortality, complications, infection risk and real-time clinical data. These models could be integrated into routine ECMO practice, into electronic health records or ECMO monitoring systems, to generate time-updated and interpretable risk alerts to inform early intervention, antimicrobial stewardship, and resource planning.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bianca M Iacopetta, Niranjan Ananda Setty, Chloe Charlesworth, Michaela Donaghy, Carolyn J Peddle-McIntyre, Ai Ling Tan, Y C Gary Lee
{"title":"The PASE Study: The Prevalence and Associations of Bendopnoea in Patients with Pneumothorax.","authors":"Bianca M Iacopetta, Niranjan Ananda Setty, Chloe Charlesworth, Michaela Donaghy, Carolyn J Peddle-McIntyre, Ai Ling Tan, Y C Gary Lee","doi":"10.3390/arm94050068","DOIUrl":"10.3390/arm94050068","url":null,"abstract":"<p><p><b>Background:</b> We recently established that bendopnoea (breathlessness upon bending forward) is common with pleural effusion; however, it has never been reported or investigated in patients with pneumothorax. This exploratory study investigated the prevalence and clinical relevance of bendopnoea in pneumothorax. <b>Methods:</b> Patients with pneumothorax of any aetiology or size were eligible. The presence of bendopnoea and time-to-bendopnoea was measured by bending the patient forward for 60 s and was assessed at baseline and post lung re-expansion. <b>Results:</b> Fifty patients (median age 48 years; 78% male) with primary spontaneous (48%), secondary spontaneous (24%) or iatrogenic (28%) pneumothorax were included. Pneumothorax size ranged from 7 to 99% of the hemithorax on chest radiographs. Most patients (74%) received conservative management. On a questionnaire, 48% (24/50) patients reported they experienced bendopnoea which \"impacted daily life\". When bent forward, 32% (16/50) developed bendopnoea within 60 s. Patients with bendopnoea reported more breathlessness than those without bendopnoea on a 100 mm Visual Analogue Scale (VAS): median 46 [Q1-Q3 = 25-54] vs. 12 [3-32] mm, respectively, <i>p</i> = 0.0089; median difference -23 mm (95% CI -35 to -6). Those with bendopnoea showed a signal with worse chest pain on a 100 mm VAS for pain: median 28 [13-48] vs. 10 [2-42] mm, <i>p</i> = 0.0528; median difference -15 mm (95% CI -27 to 0). Shorter time-to-bendopnoea (i.e., worse bendopnoea) correlated with worse breathlessness (r<sub>s</sub> = -0.38, 95% CI -0.6 to -0.1; <i>p</i> = 0.0072) and more severe chest pain (r<sub>s</sub> = -0.29, 95% CI -0.5 to -0.007; <i>p</i> = 0.039). <b>Conclusions:</b> Bendopnoea can occur with pneumothorax, correlates with breathlessness and demonstrates a signal with worse chest pain.</p>","PeriodicalId":7391,"journal":{"name":"Advances in respiratory medicine","volume":"94 5","pages":""},"PeriodicalIF":4.5,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13701407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}